Search results
Results From The WOW.Com Content Network
Ampicillin/sulbactam is contraindicated in individuals who have a history of a penicillin allergy. Symptoms of allergic reactions may range from rash to potentially life-threatening conditions, such as anaphylaxis. Patients who have asthma, eczema, hives, or hay fever are more likely to develop undesirable reactions to any of the penicillins. [10]
If someone has developed side effects when taking penicillin, these side effects may develop with a new medication even though the person has not taken the new medication before. Those medications that may cause a cross sensitivity reaction are: carbapenems, ampicillin, cefazolin, cephalosporins and cloxacillin. [9] [8] [10]
Unasyn is the trade name for two related antibiotic drugs: Ampicillin/sulbactam , a fixed-dose combination medication of the penicillin antibiotic combination ampicillin/sulbactam Sultamicillin , an oral form of the penicillin antibiotic combination ampicillin/sulbactam
Sultamicillin, sold under the brand name Unasyn among others, is an oral form of the penicillin antibiotic combination ampicillin/sulbactam. It is used for the treatment of bacterial infections of the upper and lower respiratory tract , the kidneys and urinary tract , skin and soft tissues , among other organs.
Cross-reactivity, in a general sense, is the reactivity of an observed agent which initiates reactions outside the main reaction expected. This has implications for any kind of test or assay , including diagnostic tests in medicine, and can be a cause of false positives .
Type IV hypersensitivity, in the Gell and Coombs classification of allergic reactions, often called delayed-type hypersensitivity, is a type of hypersensitivity reaction that can take a day or more to develop. [1] Unlike the other types, it is not humoral (not antibody-mediated) but rather is a type of cell-mediated response.
In 1966, the World Health Organisation confirmed the Kirby–Bauer method as the standard method for susceptibility testing; it is simple, cost-effective and can test multiple antibiotics. [25] The Etest was developed in 1980 by BolmstrÓ§m and Eriksson, and MALDI-TOF developed in 2000s. [25]
When in 1981 Rob Aalberse from the University of Amsterdam noticed the enormous cross-reactivity of some patients´ sera against virtually any plant and even insects, notably, insect venoms, [1] it took ten years to arrive at a possible structural explanation of this phenomenon. 1991, Japanese researchers determined the structure of the epitope common to horseradish peroxidase and Drosophila ...